Stichwörter: Germany; Randomized Controlled Trials as Topic; Combined Modality Therapy; Spinal Cord; Multicenter Studies as Topic; Antineoplastic Combined Chemotherapy Protocols; Registries; Adolescent; Radiation Injuries; Retrospective Studies; Melphalan; Ifosfamide; Survivors; Sarcoma Ewing's; Child; Vincristine; Bone Neoplasms; Dactinomycin; Humans; Radiotherapy Adjuvant; Intestines; Lung; Cross-Sectional Studies; Busulfan; Risk Factors; Radiotherapy Dosage; Dose-Response Relationship Drug; Chemotherapy Adjuvant; Germany; Randomized Controlled Trials as Topic; Combined Modality Therapy; Spinal Cord; Multicenter Studies as Topic; Antineoplastic Combined Chemotherapy Protocols; Registries; Adolescent; Radiation Injuries; Retrospective Studies; Melphalan; Ifosfamide; Survivors; Sarcoma Ewing's; Child; Vincristine; Bone Neoplasms; Dactinomycin; Humans; Radiotherapy Adjuvant; Intestines; Lung; Cross-Sectional Studies; Busulfan; Risk Factors; Radiotherapy Dosage; Dose-Response Relationship Drug; Chemotherapy Adjuvant